During the corresponding time, Opthea Limited saw a revenue deteriorated by -79.95 % year on year, While revenue at the Opthea Limited's corporate clients
Opthea Limited's Comment on Sales, Marketing and Customers
The U.S. government has implemented regulatory measures targeting pharmaceutical companies' drug pricing practices. The Department of Health and Human Services (HHS) introduced the Comprehensive Plan for Addressing High Drug Prices. The Inflation Reduction Act (IRA) established a Drug Price Negotiation Program focusing on high-expenditure, single-source prescription drugs and biologics covered under Medicare Part B and Part D. This program will initiate price negotiations for ten drugs in 2026, expanding to twenty drugs by 2029, with penalties imposed for non-compliance. Additionally, various state-level legislations seek to control pharmaceutical pricing through price controls, reimbursement limitations, and encouragement of drug importation. The Centers for Medicare & Medicaid Services (CMS) oversees aspects of these programs affecting Medicare beneficiaries.
Opthea Announces Promising Findings on VEGF-C and D Signaling Pathways, A Key Milestone in Wet AMD Treatment DevelopmentOpthea, a leading biopharmaceutical company focused on developing innovative therapies for eye diseases, has recently published groundbreaking research on the VEGF-C and D signaling pathways. These findings have significant implications for the treatment of wet age-related macular degeneration (AMD), a devastating eye condition that affects millions worldwide.Wet AMD is characterized by the abnormal growth of blood vessels in the retina, causing leakage and leading to progressive vision loss if left untreated. The current standard of care involves the use of anti-VEGF therapies, which targe...
Opthea Limited: Advancing Innovative Therapies for Retinal DiseasesOpthea Limited, a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for prevalent and progressive retinal diseases, recently made several presentations at various high-profile conferences. These presentations aimed to provide updates on their clinical trial programs and shed light on the potential of their novel therapies.At the Clinical Trials at the Summit (CTS) Meeting, held in Park City, Utah on June 8, 2024, Opthea s Chief Executive Officer, Frederic Guerard, PharmD, participated in a panel discussion. The session allowed Opthea to engage with industry experts and stakeholders to share insights and o...
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMDOpthea, a leading biopharmaceutical company, has accomplished a significant milestone by completing the enrollment of 1,984 patients in its pivotal Phase 3 clinical program. This breakthrough study, consisting of the COAST and ShORe trials, is evaluating the efficacy and safety of Sozinibercept as a potential treatment for wet age-related macular degeneration (AMD).Age-related macular degeneration is a prevalent eye disease affecting millions worldwide, resulting in severe vision loss. Wet AMD is a particularly aggressive form of the condition, characterized by the growth of abnormal blood vessels beneath the retina,...
The recent achievement of Opthea Limited, an Australia-based clinical-stage biopharmaceutical company, of gaining a spot in the prestigious 23rd Annual Needham Virtual Healthcare Conference slated for April 11, 2024, is indeed a notable affair. With clinics in Australia and its shares trading on both the Australian and NASDAQ stock markets (ASX/NASDAQ: OPT), this company is unique in how it propels the trajectory of international pharmaceutical developments. Known for its innovative approach towards addressing highly common, and progressively agonising retinal diseases, such as wet age-related macular degeneration (wet AMD), this opportunity is expected to greatly enhance Opthea s visibility in the global ar...
Opthea Limited’s Comment on Sales, Marketing and Customers
The U.S. government has implemented regulatory measures targeting pharmaceutical companies' drug pricing practices. The Department of Health and Human Services (HHS) introduced the Comprehensive Plan for Addressing High Drug Prices. The Inflation Reduction Act (IRA) established a Drug Price Negotiation Program focusing on high-expenditure, single-source prescription drugs and biologics covered under Medicare Part B and Part D. This program will initiate price negotiations for ten drugs in 2026, expanding to twenty drugs by 2029, with penalties imposed for non-compliance. Additionally, various state-level legislations seek to control pharmaceutical pricing through price controls, reimbursement limitations, and encouragement of drug importation. The Centers for Medicare & Medicaid Services (CMS) oversees aspects of these programs affecting Medicare beneficiaries.
Sources:
Opthea Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Opthea Limited’s corporate clients.
For your research, we’ve provided 9 tables on Opthea Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
